Crescendo Aims for 'Full Launch Velocity' for Vectra DA, Focus on Educating RA Patients in 2013 | GenomeWeb

Originally published Jan. 8.

A portion of the $28 million that Crescendo Bioscience recently secured in financing will go toward educating rheumatoid arthritis patients about its flagship Vectra DA molecular diagnostic for assessing disease activity, according to company officials.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.